XENE News and Press, Xenon Pharmaceuticals Inc.

2024-07-09 10:32:15 ET Summary Ingrezza Sprinkle, granules, has been recently granted with the FDA approval. Supporting $2.1-2.2 billion in 2024 sales for the whole Ingrezza franchise guided by Neurocrine’s management. Neurocrine Biosciences, Inc. has two new drug applicati...

2024-06-25 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-15 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in M...

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Cli...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-15 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-09 20:05:29 ET Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Conference Call May 9, 2024, 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and CEO Dr. Chris Kenney - Chief Medical Officer D...

2024-05-09 16:41:24 ET More on Xenon Pharma Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Xenon Pharma Historical earnings data for Xenon Pharma Financial information for Xenon Pharma Read ...

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azet...